<DOC>
	<DOCNO>NCT00017095</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy work different way stop tumor cell divide stop grow die . Currently patient breast cancer treat one several similar combination drug . Analysis biomarkers tumor tissue may help doctor predict well patient breast cancer respond treatment help doctor choose best drug regimen treat patient . PURPOSE : This randomized phase III trial study give different regimen chemotherapy compare well work treat woman large operable locally advanced inflammatory breast cancer . This study also look whether analyze specific biomarker ( p53 ) tumor tissue may help doctor predict well patient respond treatment help doctor choose best drug treat patient .</brief_summary>
	<brief_title>Biomarker ( p53 Gene ) Analysis Combination Chemotherapy Followed Radiation Therapy Surgery Treating Women With Large Operable Locally Advanced Inflammatory Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Compare neoadjuvant fluorouracil , epirubicin , cyclophosphamide v docetaxel epirubicin follow radiotherapy surgery woman locally advance , inflammatory , large operable breast cancer . - Assess overall difference two arm . - Assess interaction p53 status outcomes arm . - Compare progression-free survival patient treat regimen . Secondary - Compare distant metastasis-free survival survival patient treat regimen . - Compare clinical pathological response regimens patient . - Compare toxicity regimens patient . Translational - Determine p53 status order study treatment effect p53 subgroup test interaction treatment p53 status . - Assess level agreement p53 assessment IHC method functional test yeast . - Evaluate prognostic predictive value `` high risk '' p53 mutation . - Perform survival analysis accord gene cluster define use microarrays . OUTLINE : This randomize , multicenter study . Patients stratify accord stage disease ( large T2-3 v locally advanced inflammatory ) , p53 status ( negative v positive v unknown ) , participate center . Patients randomize 1 2 chemotherapy treatment arm . - Arm I ( non-taxane arm ) : Patients receive 1 3 chemotherapy regimen comprise fluorouracil , epirubicin , cyclophosphamide ( FEC ) ( accord participate institution ) . - FEC 100 : Patients receive fluorouracil IV 15 minute , epirubicin IV 1 hour , cyclophosphamide IV 1 hour day 1 . Treatment repeat every 3 week 6 course absence disease progression unacceptable toxicity . - Canadian FEC : Patients receive oral cyclophosphamide day 1-14 epirubicin IV fluorouracil IV day 1 8 . If oral medication tolerate , patient may switch cyclophosphamide IV day 1 8 . Treatment repeat every 4 week 6 course absence disease progression unacceptable toxicity . - Tailored FEC : Patients receive fluorouracil IV 15 minute , epirubicin IV 1 hour , cyclophosphamide IV 1-2 hour day 1 . Patients also receive filgrastim ( G-CSF ) subcutaneously day 2-15 blood count recover . Treatment repeat every 3 week 6 course absence disease progression unacceptable toxicity . - Arm II ( taxane arm ) : Patients receive docetaxel IV 1 hour day 1 , 22 , 43 follow epirubicin IV 15 minute docetaxel IV 1 hour day 64 , 85 , 106 absence disease progression unacceptable toxicity . Following chemotherapy , patient may undergo loco-regional therapy comprise radiotherapy without breast conservation surgery mastectomy . Patients estrogen- and/or progesterone-receptor-positive disease also receive tamoxifen aromatase inhibitor 5 year . Two tumor sample ( incisional tricut biopsy ) take chemotherapy . Samples analyze IHC , functional test yeast , microarray analysis . Patients follow every 3 month 1 year , every 4 month 1.5 year , every 6 month thereafter . PROJECTED ACCRUAL : A total 1,850 patient accrue study within 5.5 year .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Inflammatory Breast Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm breast cancer Locally advance inflammatory disease T4ad , N , M0 OR Any T , N2 N3 , M0 Large operable T2 T3 tumors No bilateral breast cancer Frozen tumor sample available 1 incisional biopsy OR 2 trucut biopsy 14G needle Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Age : 70 Sex : Female Menopausal status : Not specify Performance status : WHO 01 Life expectancy : Not specify Hematopoietic : Neutrophil count great 1,500/mm^3 Platelet count great 100,000/mm^3 Hepatic : Bilirubin le 1.2 mg/dL SGOT le 60 IU/L Renal : Creatinine le 1.35 mg/dL Cardiovascular : LVEF normal echocardiography MUGA Other : No malignancy within past 5 year except basal cell squamous cell skin cancer carcinoma situ cervix No serious uncontrolled medical condition No uncontrolled psychiatric addictive disorder Not pregnant nursing Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior chemotherapy Endocrine therapy : Not specify Radiotherapy : No prior radiotherapy Surgery : See Disease Characteristics</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>stage II breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
	<keyword>stage IIIC breast cancer</keyword>
	<keyword>inflammatory breast cancer</keyword>
</DOC>